Predicting Early Cardiovascular Risk among HIV-Infected and Uninfected Kenyan Adults
预测感染艾滋病毒和未感染艾滋病毒的肯尼亚成年人的早期心血管风险
基本信息
- 批准号:9354370
- 负责人:
- 金额:$ 16.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAddressAdoptedAdultAdverse effectsAfricaAfrica South of the SaharaAfricanAgeAlcohol consumptionAnti-Retroviral AgentsAtherosclerosisBacterial InfectionsBiological AssayBloodBlood GlucoseBlood PressureC-reactive proteinCardiovascular DiseasesCardiovascular ModelsCentral obesityCessation of lifeChronicClinicCollaborationsCombination MedicationCommunicable DiseasesCommunitiesComplexCountryCross-Sectional StudiesDataDevelopmentDiseaseDistrict HospitalsDyslipidemiasEndocrineEpidemicEpidemiologyEuropeExposure toFastingFoundationsFutureGlucoseGlucose IntoleranceGoalsGuidelinesHIVHIV InfectionsHealthHelminthsHigh PrevalenceHospitalsHuman immunodeficiency virus testHyperlipidemiaHypertensionImmuneIncomeIndividualInflammationInflammatoryInsulin ResistanceInterleukin-6InternationalInterventionIntervention TrialInterviewKenyaLaboratory ResearchLipidsMalariaMeasuresMetabolicMetabolic syndromeMorbidity - disease rateMyocardial InfarctionObesityOpportunistic InfectionsParasitic infectionParticipantPathway interactionsPersonsPlayPoliciesPopulationPopulations at RiskPrevalencePrevention programPrincipal InvestigatorPublic HealthRNARecruitment ActivityResearchResearch InfrastructureResearch PersonnelResearch TrainingResolutionResourcesRiskRisk FactorsRoleSiteSmokingSolidStrokeStudentsTechnologyTraining ProgramsUgandaUltrasonographyUniversitiesViremiaVisitWashingtonWomanWorkantiretroviral therapybasecardiovascular disorder riskcardiovascular risk factorcareerco-infectioncohortcombatdefined contributiondisorder riskexperiencefollow-upimmune activationinnovationinnovative technologiesintimal medial thickeningmenmiddle agemortalitymultidisciplinarynew technologyoutreachpreventprogramssex
项目摘要
ABSTRACT
Despite the high prevalence of HIV in sub-Saharan Africa, cardiovascular disease (CVD) is the leading cause
of morbidity and mortality in this region. Predictors of CVD are well-established in resource-rich countries, but
whether these same risk factors are strongly associated with CVD in sub-Saharan Africa is not known.
Growing evidence from the US and Europe suggests that HIV itself may be a risk factor for CVD, through a
combination of medication side effects, inflammation and immune activation, but how HIV disease and
treatment impacts CVD risk in Kenya and other countries with generalized HIV epidemics is less well studied.
The overall goal of this proposal is to determine the prevalence of traditional and non-traditional risk factors for
CVD in HIV-infected and uninfected men and women in western Kenya. Metabolic risk factors include
hyperlipidemia, glucose intolerance and obesity, which when taken together define a metabolic syndrome
(MetS) that has been associated with myocardial infarction and stroke in high-income countries. This will be
the focus of the first aim. In the second aim, we determine prevalence and predictors of chronic inflammation
and immune activation, comparing risk factor prevalence among HIV-infected and uninfected and defining
contributions of high HIV RNA levels, antiretroviral use, and other HIV-specific risk factors among those with
HIV. In our third aim, we define rates of subclinical atherosclerosis among these Kenyan adults using high
resolution ultrasound to measure carotid intima media thickness (C-IMT). Our multidisciplinary team from the
University of Washington (UW), University of Nairobi, Kenyatta National Hospital and the Kenya Ministry of
Health will conduct this cross-sectional study of 600 participants, 300 of whom will be HIV-infected, in a part of
Kenya where >10% of the adult population is infected with HIV. We will leverage 30 years of experience doing
research and training in Kenya, and 10 years implementing studies in the Kisumu District Hospital and
surrounding community, to identify young and middle aged individuals with CVD risk factors and abnormal C-
IMT. HIV-infected men and women >30 years old will be recruited from HIV clinics and uninfected participants
at voluntary HIV testing sites and through outreach to partners. During a single follow-up visit, an interview,
blood draw, and carotid ultrasound will be performed; assays will be conducted at a local research laboratory
(glucose, lipids) and UW (Interleukin-6, highly sensitive C-reactive protein). This exploratory R21 application is
innovative in its use of new technologies to assess C-IMT in HIV-infected and uninfected Kenyans. It will lay a
solid foundation for expanding our established research infrastructure into research on CVD and non-
communicable diseases by significantly advancing our understanding of subclinical atherosclerosis and how
risk is modulated by HIV, metabolic risk factors, inflammation and immune activation. These data will be critical
to developing targeted, feasible intervention trials to combat CVD in sub-Saharan Africa over the next decade.
摘要
尽管撒哈拉以南非洲的艾滋病毒感染率很高,但心血管疾病(CVD)是主要原因
这一地区的发病率和死亡率。在资源丰富的国家,心血管疾病的预测因素是成立的,但
这些同样的风险因素是否与撒哈拉以南非洲的心血管疾病密切相关尚不清楚。
来自美国和欧洲的越来越多的证据表明,艾滋病毒本身可能是心血管疾病的一个风险因素,通过
药物副作用、炎症和免疫激活的组合,但艾滋病毒疾病和
治疗对肯尼亚和其他普遍存在艾滋病毒流行的国家的心血管疾病风险的影响研究较少。
这项建议的总体目标是确定传统和非传统风险因素在
肯尼亚西部艾滋病毒感染者和未感染者的心血管疾病。代谢风险因素包括
高脂血症、糖耐量低减和肥胖,综合起来就是代谢综合征
(METS)与高收入国家的心肌梗死和中风有关。这将是
第一个目标的重点。在第二个目标中,我们确定慢性炎症的患病率和预测因素。
和免疫激活,比较感染艾滋病毒和未感染艾滋病毒的风险因素患病率,并确定
高HIV RNA水平、抗逆转录病毒使用和其他HIV特异性风险因素对患有
爱滋病毒。在我们的第三个目标中,我们使用HIGH来定义这些肯尼亚成年人的亚临床动脉粥样硬化率。
分辨率超声测量颈动脉内膜中层厚度(C-IMT)。我们的多学科团队来自
华盛顿大学(UW)、内罗毕大学、肯雅塔国家医院和肯尼亚卫生部
卫生组织将对600名参与者进行这项横断面研究,其中300人将是艾滋病毒感染者,这是
肯尼亚有10%的成年人口感染了艾滋病毒。我们将利用30年的经验来做
在肯尼亚的研究和培训,以及在基苏木地区医院和
以确定有心血管疾病危险因素和C-反应蛋白异常的中青年个体。
IMT.将从艾滋病毒诊所和未感染的参与者中招募30岁的艾滋病毒感染男性和女性
在自愿艾滋病毒检测地点,并通过与合作伙伴进行外联。在一次后续访问,一次采访中,
将进行抽血和颈动脉超声检查;检测将在当地研究实验室进行
(葡萄糖、血脂)和UW(白介素6,高敏C反应蛋白)。这个探索性的R21应用程序是
在使用新技术评估感染艾滋病毒和未感染艾滋病毒的肯尼亚人的C-IMT方面具有创新性。它将为我们奠定一个
为将我们现有的研究基础扩展到心血管疾病和非
通过显著提高我们对亚临床动脉粥样硬化的理解以及如何
风险受艾滋病毒、代谢风险因素、炎症和免疫激活的调节。这些数据将非常关键
开发有针对性的、可行的干预试验,以在未来十年在撒哈拉以南非洲抗击心血管疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CAREY FARQUHAR其他文献
CAREY FARQUHAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CAREY FARQUHAR', 18)}}的其他基金
Subclinical cardiac dysfunction after hypertensive disorders in pregnancy
妊娠期高血压疾病后的亚临床心功能不全
- 批准号:
10002116 - 财政年份:2019
- 资助金额:
$ 16.47万 - 项目类别:
Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention
整合辅助合作伙伴服务和系统发育学以预防 HIV 和 HCV
- 批准号:
10208545 - 财政年份:2017
- 资助金额:
$ 16.47万 - 项目类别:
IMPLEMENTING ASSISTED PARTNER SERVICES TO HIV TEST AND TREAT MEN IN WESTERN KENYA
为肯尼亚西部的男性实施艾滋病毒检测和治疗的辅助合作伙伴服务
- 批准号:
9797235 - 财政年份:2017
- 资助金额:
$ 16.47万 - 项目类别:
Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention
整合辅助合作伙伴服务和系统发育学以预防 HIV 和 HCV
- 批准号:
10086117 - 财政年份:2017
- 资助金额:
$ 16.47万 - 项目类别:
Implementing Assisted Partner Services to HIV Test and Treat Men in Western Kenya
在肯尼亚西部实施艾滋病毒检测和治疗男性辅助合作伙伴服务
- 批准号:
9407079 - 财政年份:2017
- 资助金额:
$ 16.47万 - 项目类别:
Implementing Assisted Partner Services to HIV Test and Treat Men in Western Kenya
在肯尼亚西部实施艾滋病毒检测和治疗男性辅助合作伙伴服务
- 批准号:
10155081 - 财政年份:2017
- 资助金额:
$ 16.47万 - 项目类别:
Predicting Early Cardiovascular Risk among HIV-Infected and Uninfected Kenyan Adults
预测感染艾滋病毒和未感染艾滋病毒的肯尼亚成年人的早期心血管风险
- 批准号:
9231919 - 财政年份:2016
- 资助金额:
$ 16.47万 - 项目类别:
Women and HIV: Translation of Research into Practice
妇女与艾滋病毒:研究转化为实践
- 批准号:
9283645 - 财政年份:2015
- 资助金额:
$ 16.47万 - 项目类别:
Women and HIV: Translation of Research into Practice
妇女与艾滋病毒:研究转化为实践
- 批准号:
9488546 - 财政年份:2015
- 资助金额:
$ 16.47万 - 项目类别:
Improving the HIV Care Cascade in Kenya through Implementation Science Training
通过实施科学培训改善肯尼亚的艾滋病毒护理梯级
- 批准号:
10462025 - 财政年份:2013
- 资助金额:
$ 16.47万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 16.47万 - 项目类别:
Research Grant














{{item.name}}会员




